The Lung Ambition Alliance | IASLC

Breaking Through Limits: The Lung Ambition Alliance

Lung cancer – the leading cause of cancer-related death – has claimed too many lives. We’ve formed an alliance of some of the world’s top oncology minds to change that.

These scientists, specialists, advocates and architects of new medicines have come together with an ambitious goal — to break the barriers limiting progress and double five-year survival by 2025.

But we need your help to get there.

We are the Lung Ambition Alliance

The Lung Ambition Alliance combines the diverse perspectives and expertise of four leading organizations that are working to double five-year survival for lung cancer by 2025.

On nearly every continent, the 7,500 members of the International Association for the Study of Lung Cancer (IASLC) are fighting for a world without lung cancer. We believe it is within our reach to disrupt the status quo and usher in a new era of survival. To meet this goal, the IASLC has joined forces with the Global Lung Cancer Coalition (GLCC), Guardant Health and AstraZeneca on the Lung Ambition Alliance. Individually, we are four organizations with deep roots in research and treatment, working to improve understanding of lung cancer and develop advanced techniques to stay a step ahead.


The Lung Ambition Alliance is providing new funding for the TERAVOLT registry. Learn more about TERAVOLT.

LAA Partners:

Asset 1

Lung Ambition Alliance Projects

The Early Lung Imaging Confederation (ELIC): A Shared Network of Imaging Resources

ELIC builds on evidence from recent lung cancer CT screening studies that showed a link between screening and reduced lung cancer mortality.

Effective screening is critical in finding and diagnosing lung cancer early, which may lead to more therapeutic options and the potential for increased survival. 

ELIC is a new cloud-based screening registry designed to improve the multidisciplinary detection and management of early stage lung cancer, when there is still potential for a cure. Developed by an international confederation of collaborating individuals and institutions who share a vision to develop a global CT image, ELIC is supported by growing evidence from lung cancer CT screening studies that show screening may reduce mortality. 

Developed in 2018, ELIC is a globally accessible, secure system linking lung cancer screening images and biomedical data to help clinicians avoid screening backlogs. ELIC uses deep learning techniques to facilitate detailed analysis of these data to 1) improve the reliability of clinical decision-support with CT images and 2) assist in the development of precise quantitative disease biomarkers. 

The expanded pool of CT images, supported by our partners in the Alliance, has the potential to help build better analysis and detection tools and better risk models, as well as being a global platform for standardized data and quality conformance. By collecting these images across institutions and throughout the world, researchers who might only have access to a small number of CT images in their centers can interrogate thousands of images to greatly expand their knowledge base and validate software analysis tools.

 Major Pathologic Response Project

The Alliance is validating surrogate endpoints to accelerate drug approval in early settings. We are using our understanding of the molecular features of cancer to identify patients at high-risk of early relapse and who may benefit most from therapeutic intervention.

 ILC2: Initiatives in Lung Cancer Care

The ILC2 program is inviting patient and caregiver organizations registered as non-profit in their country to submit proposals for projects that can potentially transform patient care in countries around the world. The program has been created in recognition of the high variation in lung cancer management around the world, and the very specific local barriers to quality care that must be considered when developing patient-centric solutions to address them. 

The first round has closed. We will providing an update in the near future.

The IASLC Staging Project: An Evidence-Based Lung Cancer Classification System

The IASLC Staging Project is designed to standardize and improve lung cancer staging across the globe.

Accurate and timely lung cancer staging is critical in identifying appropriate treatments for patients. However, many regions have wide variations and disparities in clinical practice. We are working to standardize international lung cancer staging guidelines through the IASLC Staging Project.

The Staging Project began in 1997 to improve the Tumor, Node and Metastasis (TNM) staging system, the most commonly used system for classifying the spread of lung cancer in individual patients.Over the past two decades, the Staging Project has produced a steady stream of evidence-based recommendations for the 7th and 8th editions of the TNM. 

Since the inception, the available data set has increased from about 6,000 patients to almost 95,000–and with the reach of the Alliance, we are able to increase it even more. Currently, the IASLC, together with the Alliance,is collecting data to help inform the 9th edition of the TNM guidelines. To learn more about the IASLC Staging Project, visit

For more information about the Lung Ambition Alliance and its full set of initial projects, please visit
The Next Phase

We believe the learnings from ELIC and the IASLC Staging Project will be invaluable in helping the Alliance chart the course for improved survival rates in lung cancer. To supplement this knowledge, we want to hear your perspectives on the state of lung cancer today. Visit to join the conversation.